RxDoctor Payments Data

Tamara Mathison, OD

Optometrist · Jamestown, NDNPI 1134161706

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $544 of the $902 with a category attached, or 60.3%. 13 manufacturers reported payments, led by Glaukos Corporation at 33.3% of the total. Reporting peaked in 2019 at $516 and has fallen 83.3% since, to $86 in 2025.

$902in general payments, 2019–2025

Across 24 payments — averaging $37.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$300
  • Mallinckrodt Hospital Products Inc.$133
  • Alcon$87
  • Novartis$75
  • Coopervision Inc.$60
  • Tarsus Pharmaceuticals, Inc.$50
  • plus $197 from 7 others

What the payments were for

  • Consulting fees$30033%
  • Food & beverage$54460%
  • Gifts$192%
  • Entertainment$394%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$902 in reported general payments places this provider in the 70th percentile of 179 optometrist providers in North Dakota.

See all optometrist providers in North Dakota

Medicare billing

Part B allowed, 2024
$55,902
Medicare patients
292
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast12$7,754
LumiganBimatoprost12$6,166
VyzultaLatanoprostene Bunod16$5,236
RocklatanNetarsudil Mesylat/Latanoprost14$4,543
Travoprost19$2,779
Latanoprost128$2,164
Timolol Maleate25$862
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$13$6,16612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 179 optometrist providers in North Dakota.

Other optometrist in Jamestown

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →